Tirzepatide's Role in Managing Insulin Resistance

Clinical Efficacy and Positioning

The American Diabetes Association recommends prioritizing tirzepatide when both glycemic control and weight management are treatment goals, particularly for patients with A1C ≥1.5% above target who require potent glucose-lowering therapy 1
Tirzepatide is effective in addressing insulin resistance in overweight/obese patients with type 2 diabetes, as it improves insulin sensitivity and reduces weight, with most patients achieving significant weight loss 1, 2
The American Diabetes Association suggests considering tirzepatide as the preferred add-on agent to metformin when metformin alone is insufficient, due to its superior efficacy in improving insulin sensitivity 1, 3
Tirzepatide can be an effective alternative to insulin initiation for patients with severely uncontrolled diabetes, as it improves insulin sensitivity rather than simply providing exogenous insulin 1
Switching from other GLP-1 agonists, such as semaglutide, to tirzepatide can produce significantly greater weight reduction, up to 20.9% vs 15.8%, in patients with well-controlled diabetes but inadequate weight loss 4

When initiating tirzepatide, start at 2.5 mg subcutaneously once weekly and escalate by 2.5 mg every 4 weeks until reaching the target dose, based on glycemic response and tolerability, and monitor for insulin sensitivity improvements by tracking HbA1c, fasting glucose, weight, and HOMA-IR indices at 12-16 week intervals 1
Adjust concomitant insulin or secretagogues to prevent hypoglycemia as insulin sensitivity improves, with patients potentially requiring 20-50% reductions in insulin doses 5
Continue therapy long-term, even after achieving weight loss goals, as discontinuation may result in weight regain and return of insulin resistance 4

Hypoglycemia risk is low when tirzepatide is used without insulin or sulfonylureas, but patients on these agents require dose adjustments as insulin sensitivity improves 5
Screen for malnutrition in patients experiencing significant weight loss (>20%) and monitor for nutritional deficiencies and sarcopenia 1
Be aware of delayed gastric emptying if patients are planning elective surgery, and consider the potential for cost and access barriers despite superior efficacy 4